J Cancer 2023; 14(4):646-656. doi:10.7150/jca.81975 This issue Cite
Department of Neurosurgery, Second hospital of Shanxi Medical University, China
Background: Galactosidase alpha (GLA), a member of galactosidase (GAL) family, contributes to cancer diagnosis and targeted therapy. Up to now, neither prognosis nor immune infiltration has been demonstrated in cases with low-grade glioma (LGG). In LGG, we investigated the association between GLA expression and immune infiltration levels.
Methods: GLA expression levels in pan-cancer were evaluated utilizing the Oncomine database. In addition, GLA level was screened via analyzing the gene expression omnibus (GEO) data and the Cancer Genome Atlas (TCGA) data, and evaluated in LGG tissues and adjacent tissues by using qPCR. TIMER database was utilized for evaluating the correlation between GLA level and LGG immune infiltrates. A correlation was found between GLA levels and LGG immune infiltrates utilizing the TIMER database. Moreover, we then assessed the TIMER data to explore clinical outcome in multiple immune cells and the correction between GLA expression and immune markers.
Results: The mRNA levels of GLA were upregulated in LGG tissues. GLA expression was associated with a poor outcome of patients with LGG. Additionally, the infiltration levels of several immune cells were obviously enriched in LGG with a higher GLA level. Moreover, LGG prognosis was worsened with high GLA levels in immune cells.
Conclusions: These results suggested that GLA levels in LGG might be more predictive of immune infiltration, with potential value for assessment of tumor development.
Keywords: Low-grade glioma, Galactosidase alpha, Prognosis, Immune infiltration